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a b s t r a c t
Great progress has been made in understanding immunity to viral infection. However, infection can
occur in the context of co-infection by unrelated pathogens that modulate immune responses and/or
disease. We have studied immunity and disease during co-infection with two unrelated viruses:
Ectromelia virus (ECTV) and Lymphocytic Choriomeningitis virus (LCMV). ECTV infection can be a lethal
in mice due in part to the blockade of Type I Interferons (IFN-I). We show that ECTV/LCMV co-infection
results in decreased ECTV viral load and amelioration of ECTV-induced disease, likely due to IFN-I
induction by LCMV, as rescue is not observed in IFN-I receptor deﬁcient mice. However, immune
responses to LCMV in ECTV co-infected mice were also lower compared to mice infected with LCMV
alone and potentially biased toward effector-memory cell generation. Thus, we provide evidence for bi-
directional effects of viral co-infection that modulate disease and immunity.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Tremendous progress has been made in our understanding of
the requirements for immunity to viral infection (Braciale et al.,
2012; Wilson and Brooks 2010). In particular, animal studies
utilizing the Lymphocytic Choriomeningitis (LCMV) mouse model
of infection have led to the description of numerous fundamental
properties of the immune system including the basis for MHC
restriction of viral antigens (Zinkernagel and Doherty, 1974, 1975;
Doherty and Zinkernagel, 1975), cross-presentation of epitopes by
MHC proteins (Storni and Bachmann, 2004), T cell effector mechan-
isms to control virus infection (Buchmeier et al., 1980; Byrne et al.,
1984; Murali-Krishna et al., 1998), the generation and maintenance
of T cell memory (Lau et al., 1994; Murali-Krishna et al., 1999; Kaech
et al., 2002), and exhaustion of T cell responses during persistent
infection (Wherry, 2011; Blattman et al., 2009; Cornberg et al., 2013;
Johnson et al., 2011; Wherry et al., 2003b) reviewed in detail by
Zhou et al. (2012). Poxviruses have also been widely used to
understand how the immune system responds to infection (Miller
et al., 2008) and are currently being investigated for use as potential
vaccine vectors (Tartaglia et al., 1990) for many important human
pathogens such as HIV (Haynes et al., 2014).
Despite this progress, an important caveat to such illuminating
laboratory experiments is that they are almost always done in
isolation, under speciﬁc pathogen-free (SPF) conditions, whereas
most “real-world” infections likely occur in the context of co-
infection by unrelated pathogens that have the potential to modulate
immune responses and/or alter disease (Stelekati and Wherry, 2012).
Current studies suggest co-infection with different pathogens is a
common occurrence that can alter the progression of disease
(Stelekati and Wherry, 2012; Seki et al., 2004; Stoicov et al., 2004;
Walzl et al., 2000; Furze et al., 2006). One early example of such
interaction is exacerbation of Listeriosis in mice to lethal disease
during co-infection with LCMV (O'Connell et al., 2004; Navarini et al.,
2006). Recent studies have also shown that enteric bacterial strains
promote infection by poliovirus via mucosal routes (Kuss et al., 2011).
Another potential consequence of viral co-infection is that one virus
may supply ancillary functions or suppress immune functions for
another (Sharp and Simmonds, 2011). Such a relationship has
previously been described for Hepatitis B (HBV) and Hepatitis D
(HDV) viruses: HDV cannot form mature virions without the pre-
sence of the Hepatitis B structural proteins (Bonino et al., 1986). Co-
infection of HBV and HDV or super infection of persistently infected
HBV patients with HDV can also alter disease progression, by
increasing liver pathology resulting in poorer prognosis in patients
due to altered immune responses and type I interferon signaling in
the host (Abbas and Afzal, 2013; Alvarado-Mora et al., 2013).
In order to understand the complex relationships that may be
occuring during virus co-infection, we have studied co-infection of
mice with ectromelia virus (ECTV) and LCMV, two unrelated
viruses that are both endemic to mice. Although previous studies
of co-infection with the related vaccinia virus (VACV) and LCMV
have shown no alteration in either LCMV CD8 T cell responses or
disease, such studies may minimize the role of these interactions
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(Brenan and Zinkernagel, 1983; Valentine et al., 2012), as VACV is
not endemic to mice, and many VACV immune evasion proteins do
not function well in mice. ECTV is a DNA virus of the orthopoxvirus
family and encodes a number of proteins that block the production
of and signaling by Type I interferons (IFN-I) (Smith and Alcami,
2002; Karupiah et al., 1993). Experimental inoculation of mice
with ECTV typically results in a lethal infection in mice due to high
virus replication in the liver and acute hepatic disease (Chapman
et al., 2010; Jacoby and Bhatt, 1987). Conversely, LCMV infection of
mice results in the rapid expansion of virus-speciﬁc CD8 T cells
that limit viremia with viral control and clearance within 7 days
post infection (Wherry et al., 2003b; Oldstone and Dixon, 1968). In
striking contrast to ECTV, LCMV induces robust Type I IFN
production in mice with peak production during the ﬁrst 12–
48 h of infection (Zhou et al., 2010; Teijaro et al., 2013). Further-
more, CD8 T cell responses to LCMV in mice are highly dependent
on IFN-I signaling for sustained expansion (Aichele et al., 2006;
Kolumam et al., 2005). Infection of Interferon receptor deﬁcient
(IFNAR /) mice with LCMV results in a defective CD8 T cell
response that is unable to control infection (Ou et al., 2001).
Therefore, we hypothesize that co-infection with ECTV and LCMV
has the potential for bi-directional effects on disease and immu-
nity by IFN-I suppression of ECTV replication and disease while
limiting LCMV-speciﬁc CD8 T cell responses.
We show here that ECTV/LCMV co-infection of mice results in
decreased ECTV viral load and ameliorates ECTV-induced disease.
Furthermore, we show that this effect is likely due to IFN-I induction
by LCMV that is able to overwhelm ECTV mechanisms for suppression
of IFN-I production and signaling. Conversely, we also show that ECTV
partial suppression of IFN-I production during co-infection with LCMV
results in diminished CD8 T cell responses to LCMV. Additionally, the
LCMV response is biased towards the formation of memory CD8 Tcells
with a TNF-deﬁcient effector-memory phenotype that has been shown
to be less protective in other studies (Wherry et al., 2003a; Zaph et al.,
2004; Bachmann et al., 2005). Thus, we provide the ﬁrst experimental
evidence for bi-directional effects of these two unrelated viruses
during co-infection to modulate disease and immunity. These ﬁndings
likely have implications for disease and transmission of these viruses
in wild mouse populations, but more importantly suggest that
differences in immune responses during viral infection may be in part




6–8 week old female C57Bl/6J mice were purchased from
Jackson laboratories (Bar Harbor, Maine). IFNAR1-deﬁcient mice
(IFNAR /) were purchased from Jackson laboratories (Bar Harbor,
Maine) and bred in our ASU animal facilities. All studies were
conducted according to animal protocol 12-1229R under the
approval and guidance of the Arizona State University Institute
for Animal Care and Use Committee.
Cells and viruses
BHK cells were maintained in complete Eagle's MEM (5% fetal
bovine serum (FBS), 2 mM L-glutamine (L-Q), 100 U/mL penicillin,
100 μg/ml streptomycin). Vero and MC57 cells were maintained in
complete DMEM (10% FBS, 2 mM L-Q, 100 U/ml penicillin, 100 μg/
mL streptomycin). LCMV Armstrong and LCMV clone-13 stocks
were kindly provided by Raﬁ Ahmed (Emory University, Atlanta
GA) and produced in BHK cells as previously described (Welsh and
Seedhom, 2008). The titer of LCMV stocks and mouse serum
samples were determined by plaque assay on Vero cell monolayers
as previously described (Hersperger et al., 2012). ECTV expressing
the β-gal gene in the CHO locus (US17-βgal) was a gift from Dr.
Mark Buller (St Louis University, St Louis MO). ECTV stocks were
propagated in Vero cells as previously described (Alejo et al.,
2009). ECTV titers in mouse liver homogenates were determined
on VERO cell monolayers. Brieﬂy, liver samples were weighed and
homogenized in PBS to 10% w/v. Vero monolayers were infected
following three freeze-thaw cycles for 1 h prior to overlay with a
1:1 ratio of 1% agarose and 2 -MEM supplemented with 10% fetal
bovine serum. After three days at 37 1C, the second overlay of a 1:1
ratio of 1% Agarose and 2 -MEM supplemented with 10% fetal
bovine serum and X-gal (20 mg/ml) was applied. Four days after
the secondary overlay blue ECTV plaques were counted.
In vivo infections
Unless otherwise stated, LCMV and ECTV stocks were diluted to
106 pfu/ml in 1 PBS prior to intraperitoneal infection in a volume of
100 ul, delivering a total of 105 pfu per mouse. Unless otherwise
indicated, co-infected mice received ECTV immediately followed by
LCMV inoculation. Mice were monitored daily for clinical disease
(hunched posture, rufﬂed fur, non-motility) and euthanized in
accordance with our approved IACUC protocol when terminal dis-
eases symptoms were observed at the indicated times post infection.
Peptides
Lymphocytic choriomeningitis virus CD8 T cell epitopes GP33
(H-2Db, KAVYNFATC) and NP396 (H-2Db, FQPQNGQFI) were pur-
chased from Genscript (Piscataway, NJ).
Cell surface antibody staining
Single cell suspensions were prepared from splenocytes as pre-
viously described (Murali-Krishna et al., 1998). Erythrocytes were
lysed with ammonium chloride lysis (ACK) buffer purchased from
Lonza (Allendale, NJ) and FACS staining was done as previously
described (Murali-Krishna et al., 1998) in 96 well plates with
ﬂuorochrome-labeled monoclonal antibodies: anti-CD8 (clone 53-
6.7), anti-CD44 (clone IM7), anti-PD-1 (clone J43), anti-CD4(clone
GK1.5) and anti-CD62L (clone MEL-14) or APC labeled GP33-tetramer
(Wherry et al., 2003b). Samples were then ﬁxed in 1% paraformalde-
hyde solution and immediately acquired on a BD LSR II Fortessa ﬂow
cytometer (San Jose, CA) and analyzed using FlowJo software (Tree-
Star, Ashland, OR). All surface monoclonal antibodies were purchased
from BD Pharmigen (San Diego, CA) or eBioscience (San Diego, CA).
Intracellular cytokine staining
For quantitation of ECTV-speciﬁc T cell responses, splenocytes (106/
well) were stimulated with uninfected MC57 cells or with ECTV
infected MC57 cells (MOI:1, at 24 h post infection) as previously
described (Hersperger et al., 2012). For quantitation of LCMV-speciﬁc
T cell responses, splenocytes were cultured alone or with 1 mM LCMV
peptide epitopes as previously described (Murali-Krishna et al., 1998).
After 5 h of stimulation, cells were permeabilized and intracellular
cytokine producing cells detected by staining with anti-IFNg (clone
XMG1.2) and anti-TNF (clone MP6-XT22) antibodies purchased from
BD Pharmigen (San Diego, CA) or eBioscience (San Diego, CA). The
samples were acquired and analyzed as described above.
Interferon-I ELISA
Mouse interferon beta and interferon alpha ELISA kits were
purchased from PBL Assay Science (Piscataway, NJ) and used
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according to manufacturer's instructions to detect serum Type I
IFN levels.
Histology
Formalin ﬁxed liver sections were cut into 20 μm thick tissue
sections on a microtome. Liver samples were stained with x-gal
(20mg/mL) using the β-galactosidase reporter gene staining kit
purchased from Sigma (St Louis, MO) following the manufacturer's
instructions. Adjacent sections of formalin ﬁxed liver tissue were
stained with hematoxylin and eosin as previously described (Fischer
et al., 2008). 20x images were takenwith a Zeiss Axioskop (Thornwood,
NJ) and evaluated for pathology and punctate blue x-gal staining.
Statistics
Prism software (Graphpad, La Jolla, CA) was used to calculate t-
test p values to determine signiﬁcance or log-rank test to determine
survival curve signiﬁcance (*¼pr0.05, **¼pr0.01, ***¼pr0.001).
Results
ECTV/LCMV co-infection reduces ECTV disease and viral load
We ﬁrst determined if ECTV/LCMV co-infection alters disease in
mice compared to ECTV infection alone, by monitoring physical
symptoms and mouse survival. As expected, mice infected with ECTV
alone exhibited extreme disease symptoms starting at 5 days post
infection and required euthanasia by 7 days post infection (Fig. 1A).
Surprisingly, 6 week-old ECTV/LCMV co-infected mice exhibited a
delay in ECTV-induced disease, with survival between 12 and 17 days
post infection, more than twice that observed in mice infected with
ECTV alone. As Orthopoxvirus infections have been shown to be age
and immune status dependent, with older mice typically having
reduced poxvirus replication and less severe disease (Esteban and
Buller, 2005), we also compared mice infected with ECTV alone to
ECTV/LCMV co-infection in 8-week old mice. We observed no differ-
ence in ECTV disease in older mice compared to younger mice,
presumably due to the high dose of inoculation used, since all mice
infected with ECTV alone required euthanasia by 7 days post-infection.
In striking contrast, 70% of 8 week-old ECTV/LCMV co-infected mice
exhibited long-term disease-free survival. Overall, ECTV/LCMV co-
infection resulted in 50% survival of mice, with no detectable ECTV in
liver homogenates at 460 days post infection compared to 0% survival
after mice infected with ECTV alone. Thus, these results demonstrate
that ECTV/LCMV co-infection can ameliorate ECTV disease in mice.
ECTV induced mortality in mice is known to correlate with high
viral titers in the liver that result in in acute hepatic failure (Esteban
and Buller, 2005; Xu et al., 2012). In order to determine whether the
delay in and/or amelioration of ECTV-induced disease in ECTV/LCMV
co-infected mice was due to suppression of ECTV viral loads, we next
measured ECTV viral titers in the liver of ECTV/LCMV co-infected mice
compared to mice infected with ECTV alone. Mice infected with ECTV
alone exhibited high liver viral titers, with up to 109 pfu/gram by 6 days
post-infection (Fig. 1B). However, ECTV/LCMV co-infected mice exhib-
ited a 1000 to 100-fold decrease in ECTV liver viral load, remaining
below 107 pfu/gram up to 9 days post infection. Thereafter, ECTV/LCMV
co-infected mice were either able to completely control ECTV infection
or succumbed to lethal disease. Notably, in analysis of liver tissue
sections directly ex vivo, mice infected with ECTV alone displayed
punctate x-gal staining across the entire liver section, whereas x-gal
stainingwas undetectable in ECTV/LCMV co-infectedmice at day 5 post
infection (Fig. 1C, top panel). These ﬁndings were also consistent with
histological staining (H&E stain) in which liver tissues at 5 days post
infection frommice infectedwith ECTV alone showedmultiple necrotic
lesions, whereas liver sections from ECTV/LCMV co-infected mice did
not exhibit any detectable necrotic lesions (Fig. 1C, bottom panel).
Taken together, these results show that ECTV/LCMV co-infection
reduces ECTV virus load in the liver and therefore ameliorates disease.
In order to investigate if the reduced disease in ECTV/LCMV co-
infected mice was due to LCMV prevention of initial ECTV infection of
cells, versus suppression of ECTV replication, we tested whether
infection of mice with decreasing doses of ECTV during LCMV co-
infection had a similar effect on disease and viral loads. We reasoned
that if LCMV inhibited initial seeding of ECTV in the liver we would
expect mice receiving lower doses of ECTV to also have less disease
and enhanced survival in the absence of LCMV infection. Mice that
received up to 1000-fold lower doses of ECTV exhibited similar disease
at 5 days post-infection compared to the high dose inoculation used
above, and 100% of these mice required euthanasia by 7 days post
infection. Surprisingly, lower inoculum doses of ECTV during ECTV/
LCMV co-infection had no impact on suppression of disease: ECTV/
LCMV co-infected mice at all doses of ECTV demonstrated delayed
disease until day 16 post infection and had no statistical difference in
the percentage of mice that survived long-term, similar to that
observed during high dose infection (Fig. 1D). These data are con-
sistent with the hypothesis that the observed suppression of ECTV
disease in ECTV/LCMV co-infected mice is not due to competition for
target cells or blockade of initial ECTV seeding in the liver, but rather
suppression of ECTV replication or infection after initial seeding.
The timing of LCMV infection is crucial for reducing disease during
ECTV co-infection
We next hypothesized that the observed reduction in ECTV
replication and disease during LCMV co-infection may be dependent
on the timing (prior exposure or post exposure) of LCMV infection due
to the potential for enhancement of early innate events by LCMV to
suppress ECTV infection. Infection with LCMV up to 2 days prior to
ECTV infection resulted in similarly reduced ECTV viral loads and
disease as observed during concurrent ECTV/LCMV co-infection
(Fig. 2A). Mice infected with LCMV 3 days prior to ECTV infection
demonstrated a minor delay in disease progression, with mice
surviving on average 3 days longer than mice infected with ECTV
alone. In striking contrast, mice inoculated with LCMV 1 or 2 days post
ECTV infection showed no reduction in ECTV viral loads or disease
compared to mice infected with ECTV alone, with 100% of these mice
exhibiting lethal disease symptoms by 7 days post-infection (Fig. 2B).
Thus, the timing of co-infection for the suppression of ECTV replication
and disease suggests that the effects of LCMV on ECTV are to enhance
early innate events to suppress ECTV viral infection in the liver.
ECTV/LCMV co-infection nulliﬁes ECTV abrogation of IFN-I production
Because LCMV is known to induce potent Type I Interferon
responses (Teijaro et al., 2013), and ECTV is sensitive to Type I
Interferons (Karupiah et al., 1993; Xu et al., 2012), we next
hypothesized that the early innate immune suppression of ECTV
could be due to an overwhelming IFN-I response. This would be
consistent with the observation that LCMV inoculation 1–2 days
prior to ECTV infection resulted in similar reduction in disease and
ECTV liver titers, as Type I IFN production is maximal at 1–2 days
post LCMV infection and is curtailed thereafter (Zhou et al., 2010).
Serum levels of total IFNα and IFNβ in ECTV infected mice were
undetectable, as expected, presumably due to the ability of ECTV
viral proteins to completely shut down IFN-I production (Esteban
and Buller, 2005). In contrast, mice infected with LCMV alone
induced potent IFN-I responses, with 412,000 pg/mL total IFNα
and 4500 pg/mL IFNβ in the serum of mice infected with LCMV
alone by 24 h post infection. Thereafter, IFNα and IFNβ levels
decreased to 9000 pg/mL and 100 pg/mL respectively by 48 hours
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in mice infected with LCMV alone and were low to undetectable
thereafter (Fig. 3A and B). Although ECTV/LCMV co-infected mice
also exhibited an increase in serum levels of both IFNα and IFNβ,
compared to mice infected with ECTV alone, IFNβ levels were lower
in ECTV/LCMV co-infected mice compared to mice infected with
LCMV alone. IFNα levels were not statistically different between
LCMV and co-infected animals. Thus, these results suggest that
although ECTV is able to partially attenuate IFN-I production during
LCMV co-infection, sufﬁcient IFN-I levels remain to suppress ECTV
replication and ameliorate disease.
In order to directly test the role of IFN-I in suppression of ECTV
replication and disease during ECTV/LCMV co-infection, we tested
whether ECTV/LCMV co-infection could rescue IFNAR / mice from
disease. Mice infected with ECTV alone and ECTV/LCMV co-infected
mice had indistinguishable ECTV viral loads and exhibited similar
disease, requiring euthanasia by 7 days post-infection (Fig. 3C). Thus,
LCMV co-infection does not rescue IFNAR / mice from lethal ECTV
disease. These results suggest that Type I IFN signaling is the main
mechanism for LCMV suppression of ECTV replication and disease.
LCMV co-infection does not signiﬁcantly enhance ECTV-speciﬁc CD8 T
cell responses
Resistance to mousepox has been shown to correlate with rapid,
more enhanced cytotoxic responses (Jacoby and Bhatt, 1987; Chaudhri
et al., 2004). Therefore, an alternative explanation for the observed
decrease in ECTV disease during LCMV co-infection is that LCMV alters
ECTV-speciﬁc adaptive immune responses, and thus attenuates immu-
nopathology. It should be noted that although no studies have shown
a dependence on Type I IFN for induction of ECTV T cell responses, as
has been shown with LCMV, other Orthopoxviruses do not require
Type I IFN for induction of CD8 T cell immunity (Brenan and
Zinkernagel, 1983). We observed no difference in the ECTV-speciﬁc
CD8 T cell response between mice infected with ECTV alone or ECTV/
LCMV co-infected mice at 5 days post infection when disease
symptoms became apparent (Fig. 4A and B). Moreover, in both groups
of mice the CD8 T cells had equivalent production of IFNγ and TNF
(data not shown). Thus, LCMV co-infection does not appear to alter
initial ECTV CD8 T cell responses, or immunopathology resulting from
these cells, but rather the observed effects of co-infection on reduction
of ECTV replication and amelioration of disease are likely limited to
alteration of innate immune production of IFN-I.
Decreased IFN-I during ECTV/LCMV co-infection limits LCMV-speciﬁc
CD8 T cell expansion
In addition to the effect of LCMV co-infection to reduce ECTV
replication and disease, we next hypothesized that production of ECTV
proteins that suppress Type I IFN production (Smith and Alcami, 2002)
during LCMV co-infection may impair the generation of LCMV-speciﬁc
CD8 T cell responses that are critically dependent on Type-I IFN for
sustained proliferation (Aichele et al., 2006; Kolumam et al., 2005).
Peak LCMV CD8 T cell responses to the immunodominant GP33 and
NP396 epitopes (Wherry et al., 2003b) at 9 days post-infection
(Fig. 5A) in mice infected LCMV alone were 435% of the total CD8
T cell population with on average 46106 LCMV-speciﬁc cells.
However, ECTV/LCMV co-infection decreased the peak LCMV response
by 2–3 fold as GP33 and NP396 epitope-speciﬁc CD8 T cells comprised
Fig. 1. ECTV/LCMV co-infection reduces ECTV disease and viral load. 6-8 week old female C57Bl/6 mice were injected with 105 pfu ECTV-US17-βgal ip. Immediately following ECTV
infection co-infected mice were injected with 105 pfu LCMV Armstrong ip. All mice were monitored daily for morbidity and mortality. [A] Survival of ECTV infected (n¼34), LCMV
infected (n¼20) and ECTV/LCMV co-infected (n¼47) 6–8 week-old mice. [B] Mean ECTV viral load (pfu/gram) in liver in ECTV infected and ECTV/LCMV co-infected mice on days
indicated post infection (n¼3–5 mice/group). [C] Top panel: 20X view of formalin ﬁxed liver section stained with X-gal at day 5 post infection. Bottom panel: Histological stain
(H&E) of formalin ﬁxed liver sections at day 5 post infection, red arrows point to necrotic lesions. [D] Survival of 8-week old female C57Bl/6 mice injected with 105, 104 or 103 pfu
ECTV-US17-βgal ip. Immediately following ECTV infection co-infected mice were injected with 105 pfu LCMV Armstrong ip (n¼3–5 mice/group).
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o20% of the total CD8 T cell population with on average o2106
LCMV-speciﬁc CD8 T cells (Fig. 5B). This effect was not due to
differences in the timing of expansion of the LCMV-speciﬁc CD8 T
cells, as a similar reduction in the effector T cell response was also seen
at 7 and 9 days post ECTV/LCMV-infection (Fig. 5C). Moreover, and
consistent with previous reports that show that Type I IFN are
necessary for sustained proliferation of CD8 T cells but not the initial
activation and early proliferation of these cells (Kolumam et al., 2005),
we observed no difference in the CD8 T cell response to LCMV
between mice infected with LCMV alone and ECTV/LCMV co-
infected mice at 5 days post-infection (Fig. 5C). Thus, incomplete ECTV
suppression of Type I IFN during LCMV co-infection results in reduced
LCMV-speciﬁc CD8 T cell expansion.
In order to determine if the route of infection of ECTV can impact
the resulting decrease in T cell immunity, LCMV-speciﬁc CD8 T cell
responses were measured during co-infection of ECTV infection via
footpad injection, which mimics the presumed natural route of ECTV
through skin abrasion. The number of LCMV-speciﬁc CD8 T cells in the
spleen was measured by IFNγ production after stimulation with GP33
and NP396 epitopes at day 9 post infection. Consistent with previous
results, co-infection with ECTV resulted in a statistically signiﬁcant,
greater than 2-fold, decrease of LCMV effector CD8 T cells at the peak
of the response (Fig. 5D). Indicating the route of infection does not
alter the potential for immune modulation during co-infection.
Additionally, although not statistically signiﬁcant with the number
of mice used in these studies, the percentage of LCMV-speciﬁc
memory CD8 T cells in ECTV/LCMV co-infected mice was consistently
lower than that observed in mice infected with LCMV alone at 435
days post infection. Thus, memory CD8 T cell populations speciﬁc for
the immunodominant NP396 and GP33 epitopes appeared to be
proportional to peak effector T cell responses in both groups. (Fig. 6A).
Decreased CD8 T cell responses to LCMV during ECTV/LCMV co-
infection do not impair control of LCMV or T cell memory function
We next asked whether the observed reduction in LCMV-
speciﬁc CD8 T cell responses during ECTV/LCMV co-infection
impaired immune control of LCMV. Surprisingly, we observed no
Fig. 2. The timing of LCMV infection is crucial for reducing disease during ECTV co-
infection. [A] Survival of 6 week-old mice infected with 105 LCMV Armstrong (ip) 1,
2 or 3 days prior to ECTV-US17-βgal (ip) infection. [B] Survival of ECTV-US17-βgal
infected 8-week old mice (d0) that received LCMV Armstrong immunization 1 or
2 days post ECTV exposure (n¼3–5 mice/group).
Fig. 3. ECTV/LCMV co-infection nulliﬁes ECTV abrogation of IFN-I production. 6–8 week old female C57Bl/6 mice were injected with 105 pfu ECTV-US17-βgal ip (100 μl).
Immediately following ECTV infection co-infected mice were injected with 105 pfu LCMV Armstrong ip. [A] IFN-alpha levels in serum of ECTV/LCMV co-infected mice as
compared to LCMV only and ECTV only control mice at 24 and 48 h post infection (n¼3–5 mice/group). [B] IFN-beta levels in serum of ECTV/LCMV co-infected mice as
compared to LCMV only and ECTV only control mice at 24 and 48 h post infection (n¼3–5 mice/group). [C] Survival of 6–8 week old female IFNAR/ mice injected with 105
pfu ECTV-US17-βgal ip (100 μl). Immediately following ECTV infection co-infected mice were injected with 105 pfu LCMV Armstrong ip (n¼3–5 mice/group).
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difference in serum LCMV titers at 7 days post-infection between
mice infected with LCMV alone and ECTV/LCMV co-infected mice,
with neither group having detectable LCMV levels at this time.
However, we cannot rule out that there were small differences in
the kinetics of control of LCMV. Many studies have suggested that
the strength or duration of the initial stimulus has a dramatic
impact on the generation and function of CD8 T cell memory
(Kaech et al., 2002; Wherry et al., 2003b; Ou et al., 2001). Although
we observed no impact of ECTV/LCMV co-infection on CD8 T cell
mediated control of LCMV, we reasoned that if the diminished CD8
T cell responses in ECTV/LCMV co-infected mice resulted in slight
impairment of LCMV-speciﬁc immunity, then this might alter the
bias generation of LCMV-speciﬁc memory T cells or their function.
To test whether LCMV-speciﬁc memory CD8 T cells in ECTV/
LCMV co-infected mice were impaired in their effector functions we
next measured the ability of memory cells from mice infected with
LCMV alone or ECTV/LCMV co-infected mice to produce the key
cytokines IFNγ and TNF. We observed a decrease in the relative
proportions of memory cells, speciﬁc for NP396 and GP33 epitopes,
that were positive for both IFNγ and TNF: 89% of CD8 T cells
producing IFNγ in response to these epitopes in mice infected with
LCMV alone were double-positive for TNF while only 41% IFNγ
positive LCMV-speciﬁc CD8 T cells in ECTV/LCMV co-infected mice
also produced TNF (Fig. 6B). Moreover, the number of central-
memory (CD62Lhigh) CD8 T cells speciﬁc for GP33 was decreased
three-fold in ECTV/LCMV co-infected mice compared to mice
infected with LCMV alone (Fig. 6C). Taken together, these results
suggest that CD8 T cell control of LCMV is partially impaired in ECTV
co-infected mice resulting in less functional memory cells that may
be biased toward an effector-memory (CD62Llow) phenotype.
Finally, we tested whether the reduced cytokine production and
effector-memory bias of CD8 T cell populations in ECTV/LCMV co-
infected mice impacted the ability of these mice to control sub-
sequent LCMV infection. We challenged ECTV/LCMV co-infected or
mice infected with LCMV alone at memory time points (60 days
post-infection) with the virulent clone-13 strain of LCMV (Sullivan
et al., 2011; Ahmed et al., 1984; Smelt et al., 2001). Both groups of
mice, whether previously infected with LCMV alone or with ECTV/
LCMV, and challenged with LCMV clone-13 at 60 days post-
infection, had undetectable LCMV viral titers in the serum at 7 days
post-challenge (Fig. 6D). In contrast, non-immunized mice infected
with LCMV clone-13 were unable to control LCMV replication and
had high viremia (105 pfu/ml) in the serum at 7 days post-
infection. NP396 or GP33 speciﬁc memory CD8 T cells from either
ECTV/LCMV co-infected or mice infected with LCMV alone
expressed low levels of PD-1, an inhibitory protein associated with
decreased CD8 T cell function (Blattman et al., 2009), after LCMV
clone-13 challenge (Fig. 6E). Thus, although ECTV co-infection
reduced the generation and function of memory LCMV-speciﬁc
CD8 T cell populations, in addition to biasing these cells to an
effector-memory phenotype which has been shown to be less
protective during LCMV challenge (Wherry et al., 2003a;
Bachmann et al., 2005), sufﬁcient memory T cells persisted in both
groups to mount protective responses to LCMV clone-13 challenge.
Discussion
Our results demonstrate interaction between endemic but unre-
lated viruses during co-infection of mice to limit disease and
immunity. Mice co-infected with LCMV and ECTV demonstrated
reduced ECTV replication resulting in reduced disease and enhanced
survival. Conversely, ECTV co-infection resulted in reduced LCMV-
speciﬁc CD8 T cell responses. The data suggest that these effects are
primarily due to modulation of Type I IFN levels, with primarily
lower IFNβ levels in ECTV/LCMV co-infected mice compared to mice
infected with LCMV alone and no difference in disease progression
during ECTV/LCMV co-infection in IFNAR-/- mice compared to mice
infected with ECTV alone. This is further supported by more striking
amelioration of disease in ECTV/LCMV co-infected older mice in
which Type I IFN signaling has previously been shown to limit
Orthopoxvirus replication (Xu et al., 2012).
Our results implicate Type I IFN production and/or signaling as
the main mechanism by which LCMV suppresses ECTV replication
and disease in ECTV/LCMV co-infected mice. The kinetics of LCMV
infection and induction of Type I IFN responses in this model appears
to be critically important as co-infection with LCMV 3 days prior had
minimal impact on ECTV disease while inoculation with LCMV 41
day after ECTV infection showed no effect. We suggest in the former
case LCMV-induced Type I IFN production is curtailed after 3 days to
levels that are effectively blocked by ECTV proteins. In contrast,
LCMV infection after establishment of ECTV infection is likely
ineffective as ECTV proteins have effectively shut down Type I IFN
signaling (Esteban and Buller, 2005; Brownstein et al., 1993). Our
results also show that ECTV modulation of Type I IFN production
during ECTV/LCMV co-infection attenuates LCMV-speciﬁc CD8 T cell
responses that are dependent on direct signaling via Type I IFN for
sustained proliferation. It is unlikely in this context that ECTV is
modulating Type I IFN intracellular signaling as ECTV is not known to
directly infect CD8 T cells Although we ﬁnd minimal differences in
IFNα in ECTV/LCMV co-infected mice compared to mice infected
with LCMV alone, we did observe signiﬁcantly and consistently lower
levels of systemic IFNβ in co-infected mice. Therefore, our data
suggests that IFNβ, rather than IFNα, plays a larger role in supporting
Fig. 4. ECTV/LCMV co-infection does not signiﬁcantly enhance magnitude of ECTV-
speciﬁc CD8 T cell response. 6–8 week old female C57Bl/6 mice were injected with
105 pfu ECTV-US17-βgal ip (100 μl). Immediately following ECTV infection co-
infected mice were injected with 105 pfu LCMV Armstrong ip. At the indicated time
post infection, splenocytes were harvested, processed to single cell suspensions
and stimulated for 6 h with ECTV infected MC57 cells prior to intracellular cytokine
staining. [A] Representative FACS plots of the ECTV-speciﬁc CD8 T cell response at
day 5 post infection in the spleen from ECTV infected and ECTV/LCMV co-infected
mice. [B] Mean percentage of (left panel) and total number (right panel) of ECTV-
speciﬁc CD8 T cells in the spleen on day 5 post infection as measured by IFNγ
production (n¼3–5 mice/group).
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sustained CD8 T cell proliferation during LCMV infection. In addition
to lower overall effector and memory T cell responses in ECTV/LCMV
co-infected mice, we also show that ECTV partial suppression of Type
I IFN during LCMV co-infection results in decreased memory CD8 T
cell functionality and potential biasing towards an effector-memory
phenotype. While we observed no difference in the ability of
memory cells in either group to control subsequent LCMV infection,
it has been shown that central-memory are better able to control
LCMV infection compared to effector-memory cells (Kaech et al.,
2002). Taken together with the decreased TNF production by these
cells, our results suggest that ECTV co-infection results in a slight
impairment of LCMV-speciﬁc immunity.
The importance of type I interferon to limit ECTV disease is well
known (Smith and Alcami, 2002; Karupiah et al., 1993). It has
previously been shown that antibody blockade of ECTV type I
interferon-binding protein, C12R, during ECTV infection drastically
reduces ECTV disease (Xu et al., 2012). Therefore, our results indicate
that Type I IFN produced after LCMV infection may be overwhelming
the ability of C12R to block signaling, mimicking antibody blockade. It
is currently unknown which ECTV-encoded proteins provide the
suppressive effects on Type I IFN production that result in attenuation
and alteration of LCMV-speciﬁc CD8 T cell immunity. We propose that
the most likely candidate in this case is the ECTV dsRNA binding
protein (homolog of Vaccinia virus E3L) that would be able to limit
type I interferons during co-infection (Smith and Alcami, 2002; Chang
et al., 1992; Langland and Jacobs, 2002). The ECTV IFN-I binding
protein has been shown to only block the action of mouse IFNα
(Smith and Alcami, 2002). Our results suggest there is only a decrease
in systemic IFNβ, indicating a different mechanism other than ECTV
expression of an IFN-I binding protein, is responsible for limiting
LCMV-speciﬁc CD8 T cell immunity. Interestingly, previous reports
that showed no alteration of LCMV-speciﬁc immune responses during
co-infection with the orthopoxvirus, vaccinia virus, utilized the highly
attenuated “Lancy” vaccine strain that has low virulence in mice
(Brenan and Zinkernagel, 1983).
The discovery of viral genomes incorporated within mammalian
genomes indicates that viral families are much older than pre-
viously believed (Katzourakis and Gifford, 2010). The newly pre-
dicted timescale increases the frequency of potential viral co-
divergence with hosts in order for the virus to survive (Sharp and
Simmonds, 2011). In addition, hosts that are infected with multiple
viruses or host that are persistently infected and undergo additional
Fig. 5. Decreased IFN-I during ECTV/LCMV co-infection limits LCMV-speciﬁc CD8 T cell expansion. 6–8 week old female C57Bl/6 mice were injected with 105 pfu ECTV-US17-
βgal ip (100 μl). Immediately following ECTV infection co-infected mice were injected with 105 pfu LCMV ip. At the indicated times post infection, splenocytes were
harvested, processed to single cell suspensions and stimulated for 6 h with cognate LCMV peptides prior to intracellular cytokine staining. [A] Representative FACS plots of
the LCMV-speciﬁc (GP33 peptide stimulated) CD8 T cell response in the spleen at day 9 post infection of LCMV infected and ECTV/LCMV co-infected mice. [B] Mean total
number of LCMV-speciﬁc (GP33 and NP396) CD8 T cells in the spleen (as measured by IFNγ production after peptide stimulation) on day 9 post infection [C] Mean LCMV-
speciﬁc (GP33 and NP396) response as a percentage of total CD8 T cell population in LCMV infected and ECTV/LCMV co-infected mice at day 5, 7 and 9 post infection (n¼3–5
mice/group). [D] 8 week old female C57Bl/6 mice were injected with 105 pfu ECTV-US17-βgal via the footpad route (20 μl). Immediately following ECTV infection co-infected
mice were injected with 105 pfu LCMV ip. Mean total number of LCMV-speciﬁc (GP33 and NP396) CD8 T cells in the spleen (as measured by IFNγ production after peptide
stimulation) on day 9 post infection (n¼3–5 mice/group).
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infection with an unrelated virus could result in further viral co-
evolution. The beneﬁcial interplay via modulation of IFN-I between
LCMV and ECTV suggest that there may have been co-evolution of
ECTV and LCMV in wild mouse populations due to the potential
increase in viral transmission of both viruses.
An important point that these studies raise is whether co-
infection alters either ECTV or LCMV transmission in wild mouse
populations. ECTV is suspected to be easily transmitted among
naturally infected wild populations of mice (Esteban and Buller,
2005; Fenner, 1981). Multiple ECTV strains with varying disease
severity have been isolated from outbreaks in European and North
American laboratory mouse colonies (Mavian et al., 2014; Osterhaus
et al., 1981; Osterrieder et al., 1994). The delayed progression of
ECTV disease during LCMV co-infection that results in continued
host survival may lead to greater potential for transmission of ECTV
to subsequent hosts. In addition, decreased CD8 T cell immunity and
function during ECTV co-infection could also result in a decreased
ability to control infection, potentially leading to increased trans-
mission of both ECTV and LCMV. Although we observed no
difference in LCMV control in this experimental setting using the
Fig. 6. Decreased CD8 T cell responses to LCMV during ECTV/LCMV co infection do not impair control of LCMV but bias T cell memory function. 6–8 week old female C57Bl/6
mice were injected with 105 pfu ECTV-US17-βgal ip (100 μl). Immediately following ECTV infection co-infected mice were injected with 105 pfu LCMV ip. LCMV immune mice
were infected with only 105 pfu LCMV Armstrong ip. After a period of at least 35 days, surviving co-infected mice and LCMV immune mice were challenged with 2106 pfu
LCMV-clone 13 iv or used to enumerate LCMV CD8 T cell memory formation and function. At the indicated times post infection, splenocytes were harvested, processed to
single cell suspensions and stimulated for 6 hours with cognate LCMV peptides prior to intracellular cytokine staining. [A] Kinetics of LCMV-speciﬁc (GP33 and NP396) CD8 T
cell response as a percentage of total CD8 T cells in the spleen in ECTV co-infected mice and LCMV immune mice (n¼3–5 mice/group). [B] Functional analysis of GP33 and
NP396 memory CD8 T cells at day 35 post infection. White bar indicates ability to produce IFNγ, black sections indicates ability to produce both TNF and IFNγ after peptide
stimulation (n¼3–5 mice/group). [C] Number of CD62L-high, GP33-tetramer positive CD8 T cells in the spleen at day 35 post infection in LCMV infected and ECTV/LCMV co-
infected mice (n¼3–5 mice/group). [D] LCMV clone 13 viral load (pfu/ml) in the serum of LCMV clone-13 challenged mice at day 7 post infection (n¼3–5 mice/group). [E]
Percentage of PD-1high GP33-tetramer positive cells at day 15 post-challenge in LCMV immune, ECTV/LCMV co-infected and naïve mice (n¼3–5 mice/group).
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acute Armstrong strain of LCMV, circulating LCMV strains in the
wild also include persistent strains (Oldstone and Dixon, 1968;
Becker et al., 2007; Althaus et al., 2007). Future experiments will
need to address how ECTV modulates Type I IFN during infection
during co-infection with persistent strains of LCMV or in estab-
lished carrier mice infected at birth with the virus. However, recent
data suggest that Type I IFNs produced during later time points of
persistent LCMV infection actually contribute to persistence by
suppressing immune responses (Teijaro et al., 2013). Therefore,
our results would be consistent with a more important role for
ECTV suppression of LCMV Type I IFNs during co-infection resulting
in early suppression of immunity.
An important observation in these studies is that viral co-
infection can alter the magnitude, function, and phenotype of CD8
T cell responses of the unrelated co-infecting virus. One potential
implication of viral co-infection may be variation of T cell responses
during vaccination and/or viral infection, thus the range of
responses seen between individuals (Pereyra et al., 2008; Brodin
et al., 2015; Li et al., 2014) may be in part explained by the context
of other infections. This may be relevant for vaccination studies,
using recombinant orthopoxviruses as vaccine vectors for other
pathogens (Tartaglia et al., 1990), since individuals with other
infections (or other vaccinations) may attenuate the effectiveness
of such strategies due to innate immune modulation.
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